Researchers are investigating a rare genetic disorder, Laron syndrome, for potential insights into cancer prevention. Individuals with Laron syndrome, characterized by a deficiency in the growth hormone receptor, have shown a notably lower incidence of cancer compared to the general population.
This finding has spurred scientific interest in understanding the underlying mechanisms that might confer this protective effect. The disorder affects individuals' ability to grow, leading to short stature.
For those with Laron syndrome, a medication called Increlex has been available for 15 years. This drug can promote increased height if administered during childhood growth spurts. However, access to Increlex is limited by several factors. It is only approved for children between the ages of two and 18, and its use can be associated with serious side effects. The medication's high cost, with one bottle potentially exceeding $800, and its production by a single pharmaceutical company, further complicates accessibility. A child typically requires at least three bottles per month, amounting to approximately $2,400.
Mayra Loaiza, a resident of Piñas, has experienced these challenges firsthand. Her two-year-old daughter, Camila, was scheduled to begin treatment six months ago but has yet to receive her first dose. Loaiza expressed concern about the potential impact on her daughter's growth and the risk of discrimination due to her size, while remaining hopeful that the drug will help Camila achieve normal growth.
Twins María Luisa and María del Cisne, now 40, are among those who have aged beyond the window for Increlex treatment. They reflect on how their lives might have been different had the medication been available during their youth. "We now accept ourselves as we are, but the treatment would have saved us a lot of heartache," stated María Luisa. Both sisters have come to accept their stature, with María Luisa adding, "I've accepted myself as I am, I accept myself, and I thank God for who I am."
